Introduction
Immunotherapy for prostate cancer is an emerging field that offers hope to patients with advanced disease. This innovative approach involves using the patient's immune system to target and destroy cancer cells. Immunotherapy has shown promise in treating several types of cancer, including melanoma, lung cancer, and bladder cancer. And now, it is also being increasingly used to treat prostate cancer.
The term "immunotherapy" refers to a broad category of treatments that use the immune system to fight cancer. Immunotherapy has significantly improved the management of metastatic (a condition in which cancer spreads to different body parts) cancer in recent years and changed the accepted standard of care for several tumor types. Unfortunately, it has been difficult to anticipate and comprehend responses across tumor types. Yet, a small number of patients with prostate cancer have responded admirably to cells and immunotherapy, indicating that it is worthwhile for future investigation.
What Is Immunotherapy?
Immunotherapy helps patients to fight prostate cancer. Immunotherapy trains the patient’s immune system to recognize and fight against prostate tumors. Immunotherapy is a type of medical treatment that uses a person's own immune system to fight diseases such as cancer, autoimmune diseases, and infections. The goal of immunotherapy is to boost the body's natural defenses to recognize and attack abnormal cells, such as cancer cells while leaving healthy cells unharmed. An immunosuppressive microenvironment and a "cold" tumor are common descriptions of prostate cancer.
By preventing T-effector cell function, tumor-infiltrating lymphocytes (TILs) may aid in the growth of prostate cancer. It has been demonstrated that TILs from prostate cancer biopsy samples are predisposed to the T-regulatory (Treg) and T helper 17 (Th17) phenotypes, which block autoreactive T cells and antitumor immune responses. Therefore, designing treatments that could improve immunological infiltration by antigen-presenting cells (APCs) and effector T cells is of interest. Antigen-presenting dendritic cells (DCs) are crucial for CD8+ T cell activation and subsequent tumor eradication. Many studies link DC tumor infiltration with a better prognosis.
Immunotherapy works by activating the immune system to recognize and attack cancer cells. The immune system comprises different types of cells, including T-cells, B-cells, and natural killer cells, which work together to protect the body against foreign invaders like viruses and bacteria. Unfortunately, cancer cells can evade the immune system by producing proteins that suppress the immune response. Immunotherapy helps to overcome this by blocking these proteins or by activating T-cells to recognize and attack cancer cells. Prostvac, Ipilimumab, Nivolumab, Pembrolizumab, and Enzalutamide are some phase trail immunotherapy.
The following are the types of immunotherapy:
-
Checkpoint Inhibitors - Checkpoint inhibitors target proteins called PD-1 and PD-L1, found on T-cells (type of lymphocytes) and cancer cells, respectively. When PD-1 and PD-L1 bind together, they suppress the immune response, allowing cancer cells to grow and spread. Checkpoint inhibitors block this interaction, allowing T-cells to recognize and attack cancer cells.
-
Cancer Vaccines - Cancer vaccines stimulate the immune system to recognize and attack cancer cells. There are several types of cancer vaccines, including dendritic, peptide, and whole-cell. Dendritic cell vaccines take dendritic cells, specialized immune cells, from the patient's blood and expose them to cancer cells. The dendritic cells are then infused into the patient's body, stimulating the immune system to attack the cancer cells. Peptide vaccines are made by synthesizing small pieces of protein from the cancer cells, which are injected into the patient's body to stimulate an immune response. Finally, whole-cell vaccines take cancer cells from the patient and treat them with chemicals or radiation to make them more visible to the immune system. These treated cells are then infused into the patient's body, stimulating an immune response.
What Are Vaccine-Based Therapies?
Prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA), both of which have been investigated as targets for antigen-based vaccinations associated with improved prognosis, are two immunogenic antigens expressed by prostate cancer cells. The vaccines are prepared against these two antigens. Sipuleucel-T has been evaluated in three Phase III clinical trials. Median survival in the sipuleucel-T-treated patients was 25.8 months, compared to 21.7 months.
What Are Side-Effects of Immunotherapy?
The following are the side-effects of immunotherapy:
-
Fevers.
-
Chills.
-
Headache.
-
Influenza-like illness.
-
Myalgias (muscle pain).
-
Hypertension (high blood pressure).
-
Groin pain.
-
Fatigue.
-
Cough.
-
Nausea.
-
Itching.
-
Skin rash.
-
Loss of appetite.
-
Constipation.
-
Joint pain.
-
Diarrhea.
-
Life-threatening problems such as attacking own body.
What Are the Future Aspects of Immunotherapy?
Immunotherapy for prostate cancer is still in the early stages of development, and much more research is needed to determine its effectiveness and safety. However, early clinical trials have shown promising results. For example, a phase II clinical trial of the checkpoint inhibitor pembrolizumab showed a significant reduction in prostate-specific antigen (PSA) levels in patients with advanced prostate cancer. PSA is a protein produced by prostate cancer cells, and high levels of PSA in the blood can indicate the presence of prostate cancer. Another phase II clinical trial of the cancer vaccine sipuleucel-T showed a significant increase in overall survival in patients with advanced prostate cancer.
The role and timing of immunotherapy in metastatic prostate cancer are still poorly known. Although most patients may not experience beneficial outcomes, those that do can be extremely dramatic, and patients may experience an apparent remission that lasts for several months or even years. Current research seeks to clarify the consequences of PD-L1 expression, the effect of enzalutamide on PD-L1 expression, and the potential contribution of the microbiome to the immunotherapy response. Alongside checkpoint inhibition and vaccination treatments, novel medicines like CAR-T cells and BiTEs offer exciting and promising new therapy options for metastatic prostate cancer.
Conclusion
Immunotherapy aims to boost the body's natural defenses to recognize and attack abnormal cells, such as prostate antigens, while leaving healthy cells unharmed and thus fight with prostate tumors. Fever, chills, diarrhea, muscles pain, skin rashes, and groin pain are a few side effects of immunotherapy. Immunotherapy offers a promising new approach to the treatment of advanced prostate cancer. By activating the patient's immune system to recognize and attack cancer cells, immunotherapy has the potential to be an effective treatment for patients who have not responded to traditional treatments. However, more research is needed to determine immunotherapy's long-term safety and effectiveness for prostate cancer.
